F M Investments LLC Has $11.48 Million Stock Holdings in LeMaitre Vascular, Inc. (NASDAQ:LMAT)

F M Investments LLC lifted its position in LeMaitre Vascular, Inc. (NASDAQ:LMAT) by 36.6% during the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 123,545 shares of the medical instruments supplier’s stock after acquiring an additional 33,087 shares during the period. F M Investments LLC owned about 0.55% of LeMaitre Vascular worth $11,476,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in LMAT. James Investment Research Inc. purchased a new stake in shares of LeMaitre Vascular in the third quarter valued at $201,000. Conestoga Capital Advisors LLC raised its position in LeMaitre Vascular by 1.9% during the third quarter. Conestoga Capital Advisors LLC now owns 1,978,351 shares of the medical instruments supplier’s stock valued at $183,769,000 after buying an additional 36,850 shares during the period. Oak Ridge Investments LLC purchased a new stake in LeMaitre Vascular in the 3rd quarter worth about $2,020,000. Rice Hall James & Associates LLC lifted its stake in LeMaitre Vascular by 15.7% in the 3rd quarter. Rice Hall James & Associates LLC now owns 261,306 shares of the medical instruments supplier’s stock worth $24,273,000 after acquiring an additional 35,383 shares in the last quarter. Finally, Congress Asset Management Co. grew its stake in LeMaitre Vascular by 2.6% during the 3rd quarter. Congress Asset Management Co. now owns 709,316 shares of the medical instruments supplier’s stock valued at $65,888,000 after acquiring an additional 18,295 shares in the last quarter. Institutional investors and hedge funds own 84.64% of the company’s stock.

LeMaitre Vascular Trading Up 7.3 %

LeMaitre Vascular stock traded up $6.49 during trading hours on Friday, reaching $94.88. 343,645 shares of the company were exchanged, compared to its average volume of 123,348. LeMaitre Vascular, Inc. has a 12 month low of $45.96 and a 12 month high of $101.67. The firm has a market cap of $2.13 billion, a price-to-earnings ratio of 56.81, a PEG ratio of 2.33 and a beta of 0.88. The stock has a 50-day moving average of $89.59 and a 200 day moving average of $82.98.

LeMaitre Vascular (NASDAQ:LMAT) last posted its earnings results on Thursday, October 31st. The medical instruments supplier reported $0.49 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.44 by $0.05. LeMaitre Vascular had a net margin of 18.33% and a return on equity of 12.41%. The business had revenue of $54.82 million for the quarter, compared to analyst estimates of $53.50 million. During the same period last year, the business posted $0.33 EPS. LeMaitre Vascular’s revenue was up 15.6% compared to the same quarter last year. As a group, research analysts forecast that LeMaitre Vascular, Inc. will post 1.86 EPS for the current year.

LeMaitre Vascular Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Thursday, December 5th. Shareholders of record on Thursday, November 21st will be issued a $0.16 dividend. This represents a $0.64 dividend on an annualized basis and a yield of 0.67%. The ex-dividend date is Thursday, November 21st. LeMaitre Vascular’s dividend payout ratio (DPR) is currently 38.32%.

Insiders Place Their Bets

In related news, Director David B. Roberts sold 3,063 shares of the company’s stock in a transaction on Tuesday, August 13th. The shares were sold at an average price of $82.07, for a total transaction of $251,380.41. Following the completion of the transaction, the director now directly owns 14,114 shares in the company, valued at $1,158,335.98. This represents a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Company insiders own 10.79% of the company’s stock.

Analyst Upgrades and Downgrades

A number of research analysts recently commented on LMAT shares. Lake Street Capital initiated coverage on shares of LeMaitre Vascular in a research report on Friday, August 2nd. They set a “buy” rating and a $105.00 price objective on the stock. Oppenheimer reaffirmed an “outperform” rating and issued a $93.00 price target (up from $90.00) on shares of LeMaitre Vascular in a research note on Friday. Cantor Fitzgerald initiated coverage on LeMaitre Vascular in a research report on Tuesday, October 15th. They set a “neutral” rating and a $96.00 price objective for the company. StockNews.com downgraded LeMaitre Vascular from a “buy” rating to a “hold” rating in a research note on Tuesday, August 27th. Finally, Barrington Research boosted their price target on LeMaitre Vascular from $92.00 to $93.00 and gave the company an “outperform” rating in a research note on Friday. Three research analysts have rated the stock with a hold rating, six have assigned a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $94.57.

About LeMaitre Vascular

LeMaitre Vascular, Inc develops, manufactures, and markets medical devices and implants used in the field of vascular surgery worldwide. It offers human cadaver tissue cryopreservation services; angioscope, a fiberoptic catheter used for viewing the lumen of a blood vessel; embolectomy catheters to remove blood clots from arteries; thrombectomy catheters for removing thrombi in the venous system; occlusion catheters that temporarily occlude the blood flow; and perfusion catheters to perfuse the blood and other fluids into the vasculature.